CURATIS N AG (CURN) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.024x

Based on the latest financial reports, CURATIS N AG (CURN) has a cash flow conversion efficiency ratio of -0.024x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (CHF-1.05 Million ≈ $-1.33 Million USD) by net assets (CHF44.56 Million ≈ $56.34 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CURATIS N AG market capitalisation for the company's overall valuation and market capitalisation.

CURATIS N AG - Cash Flow Conversion Efficiency Trend (2002–2024)

This chart illustrates how CURATIS N AG's cash flow conversion efficiency has evolved over time, based on yearly financial data.

CURATIS N AG Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CURATIS N AG ranked by their cash flow conversion efficiency. Explore earnings quality score of CURATIS N AG to measure how well operating cash flow supports reported net income.

Company Cash Flow Conversion Efficiency
Finger Inc.
KQ:163730
0.073x
Lion Selection Group Ltd
AU:LSX
-0.007x
ImmuCell Corporation
NASDAQ:ICCC
0.096x
BIOCELTIX S.A. ZY -10
F:XI3
-0.062x
TDG Gold Corp
V:TDG
-0.226x
Paseco Co. Ltd
KQ:037070
-0.036x
Pearson PLC
LSE:PSON
0.129x
Laster Tech Corp Ltd
TW:3346
0.159x

Annual Cash Flow Conversion Efficiency for CURATIS N AG (2002–2024)

The table below shows the annual cash flow conversion efficiency of CURATIS N AG from 2002 to 2024. View CURATIS N AG (CURN) stock price for real-time trading data and today's change.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 CHF45.60 Million
≈ $57.65 Million
CHF-825.00K
≈ $-1.04 Million
-0.018x -100.30%
2023-12-31 CHF-312.00K
≈ $-394.45K
CHF-1.89 Million
≈ $-2.38 Million
6.042x +976.84%
2022-12-31 CHF6.75 Million
≈ $8.54 Million
CHF-4.65 Million
≈ $-5.88 Million
-0.689x -176.77%
2021-12-31 CHF-400.00K
≈ $-505.71K
CHF-359.00K
≈ $-453.87K
0.898x -38.98%
2020-12-31 CHF-257.00K
≈ $-324.92K
CHF-378.00K
≈ $-477.89K
1.471x +22.64%
2019-12-31 CHF-552.00K
≈ $-697.88K
CHF-662.00K
≈ $-836.95K
1.199x +160.36%
2018-12-31 CHF377.00K
≈ $476.63K
CHF-749.00K
≈ $-946.94K
-1.987x -7596.73%
2017-12-31 CHF4.68 Million
≈ $5.92 Million
CHF124.00K
≈ $156.77K
0.027x +273.50%
2016-12-31 CHF5.04 Million
≈ $6.37 Million
CHF-77.00K
≈ $-97.35K
-0.015x +23.75%
2015-12-31 CHF6.24 Million
≈ $7.89 Million
CHF-125.00K
≈ $-158.03K
-0.020x -34.08%
2014-12-31 CHF7.90 Million
≈ $9.99 Million
CHF-118.00K
≈ $-149.18K
-0.015x +92.26%
2013-12-31 CHF8.71 Million
≈ $11.01 Million
CHF-1.68 Million
≈ $-2.12 Million
-0.193x -445.52%
2012-12-31 CHF11.60 Million
≈ $14.67 Million
CHF648.00K
≈ $819.25K
0.056x +32.82%
2011-12-31 CHF7.16 Million
≈ $9.05 Million
CHF301.00K
≈ $380.55K
0.042x -82.42%
2010-12-31 CHF6.98 Million
≈ $8.82 Million
CHF1.67 Million
≈ $2.11 Million
0.239x +41.54%
2009-12-31 CHF5.88 Million
≈ $7.44 Million
CHF994.00K
≈ $1.26 Million
0.169x +105.69%
2008-12-31 CHF1.64 Million
≈ $2.08 Million
CHF-4.88 Million
≈ $-6.16 Million
-2.968x +90.51%
2007-12-31 CHF227.00K
≈ $286.99K
CHF-7.10 Million
≈ $-8.98 Million
-31.282x -10014.42%
2006-12-31 CHF9.30 Million
≈ $11.76 Million
CHF-2.88 Million
≈ $-3.64 Million
-0.309x -27.63%
2005-12-31 CHF21.67 Million
≈ $27.40 Million
CHF-5.25 Million
≈ $-6.64 Million
-0.242x -801.22%
2004-12-31 CHF37.30 Million
≈ $47.16 Million
CHF1.29 Million
≈ $1.63 Million
0.035x +188.13%
2003-12-31 CHF49.83 Million
≈ $63.00 Million
CHF-1.95 Million
≈ $-2.47 Million
-0.039x +89.09%
2002-12-31 CHF55.33 Million
≈ $69.96 Million
CHF-19.88 Million
≈ $-25.13 Million
-0.359x --

About CURATIS N AG

SW:CURN Switzerland Drug Manufacturers - Specialty & Generic
Market Cap
$113.98 Million
CHF90.15 Million CHF
Market Cap Rank
#19651 Global
#189 in Switzerland
Share Price
CHF17.50
Change (1 day)
-8.62%
52-Week Range
CHF11.30 - CHF26.00
All Time High
CHF891.52
About

Curatis Holding AG engages in the acquisition, development, and commercialization of medicines for the prevention, diagnosis, and treatment of rare and specialty care diseases. It offers its products in the areas of fentanyl, breakthrough pain, antiplatelet, metastatic hormone receptor-positive breast cancer, anti-arrhythmic, nasal oil, wilson's disease, cyanide poisoning, digoxin toxicity, antih… Read more